SCYNEXIS (NASDAQ:SCYX) Announces Earnings Results, Beats Estimates By $0.13 EPS

SCYNEXIS (NASDAQ:SCYX) announced its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.13, Zacks reports. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

SCYNEXIS Stock Performance

Shares of SCYX stock traded up $0.01 during trading hours on Wednesday, reaching $0.91. The company had a trading volume of 142,474 shares, compared to its average volume of 199,153. SCYNEXIS has a 12-month low of $0.88 and a 12-month high of $3.07. The company has a market capitalization of $34.61 million, a price-to-earnings ratio of -1.23 and a beta of 1.67. The stock has a fifty day moving average of $1.11 and a 200-day moving average of $1.26.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.